Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
University of California, Irvine
Modality
unclassified
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04868773CT.gov Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy | — | Completed | — | — | — |
NCT06221423CT.gov Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT02465060CT.gov Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tas-102 (this asset) | University of California, Irvine | P2 | CCC · 55 |
| Tipiracil | Mayo Clinic | P2 | BBB |
| Fluorouracilum | City of Hope Medical Center | P4 | BB |
| Oxaliplatin | First Affiliated Hospital of Zhejiang University | P4 | BB |
| Muamycin | City of Hope Medical Center | P3 | BB |
| Capecitabine | First Affiliated Hospital of Zhejiang University | P4 | BB |
| Irinotecan | City of Hope Medical Center | P3 | BB |
| Pentoxifylline | Tanta University | P4 | BB |
| ner1006 | Norgine | P3 | BB |
+42 more in the Colorectal Carcinoma cohort
Other indications for Tas-102
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P3 | BB · 65 |
| Hepatocellular Carcinoma | — | P3 | B · 60 |
| Colorectal Neoplasm | — | P3 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tas-102 in Colorectal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tas-102-colorectal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →